|
Daily Medical Update
Fulminant liver failure
Wednesday, September 23, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Cochrane database of systematic reviews (2026) - Meta-Analysis
Key Findings
- Across 11 randomized trials involving 681 participants, liver support systems had little to no effect on 28-day mortality (RR 0.83, 95% CI 0.58-1.19) or mortality at maximum follow-up (RR 0.82, 95% CI 0.63-1.07).
- They also showed little to no effect on serious adverse events (rate ratio 0.93, 95% CI 0.81-1.07), liver transplantation (RR 1.03, 95% CI 0.87-1.21), or multi-organ failure (rate ratio 0.92, 95% CI 0.72-1.18).
📋 Practice Implication: Use liver support as a bridge only with guarded expectations; current randomized evidence does not establish a mortality or transplant benefit, and certainty is very low.
|
Alimentary pharmacology & therapeutics (2026) - Randomized Controlled Trial
Key Findings
- Pre-emptive CRRT was associated with lower first-7-day death hazard than rescue initiation (2.2% vs 17.8%; HR 0.12, 95% CI 0.02-0.96), although 28-day survival was comparable in the intention-to-treat analysis.
- In per-protocol analysis, delayed CRRT was associated with higher 28-day mortality (80% vs 46%; HR 3.10, 95% CI 1.57-6.12), and each hour of CRRT delay increased mortality hazard (HR 1.01, 95% CI 1.00-1.02).
📋 Practice Implication: For acute liver failure with cerebral edema undergoing plasma exchange, consider early CRRT to address ammonia and hemodynamic deterioration while recognizing the pilot trial design and analysis differences.
|
Critical care explorations (2026) - Randomized Controlled Trial
Key Findings
- Both OPAL and MARS significantly reduced bilirubin and total and individual bile acids in patients with severe liver failure.
- OPAL was superior to MARS for removing protein-bound lipophilic bile acids and restoring albumin function; TGR5 activation fell by 60% with OPAL versus 39% with MARS (p = 0.051).
📋 Practice Implication: The immediate clinical signal is modality-specific biochemical detoxification and reduced TGR5 signaling; infection and survival benefits should not be inferred before outcome trials.
|
The American journal of gastroenterology (2025) - Randomized Controlled Trial
Key Findings
- Empirical antifungal therapy improved 28-day survival compared with diagnostic or biomarker-driven pre-emptive therapy (35% vs 13%; HR 0.64, 95% CI 0.47-0.88; p = 0.005).
- Treatment success and invasive fungal infection resolution were higher (37.4% vs 16.9%, p = 0.002; 45.8% vs 22.5%, p = 0.001), while in-hospital and infection-attributable mortality was lower (55.6% vs 75.9%, p = 0.003).
📋 Practice Implication: In high-risk acute-on-chronic liver failure with clinical suspicion of invasive fungal infection, early empirical coverage within a structured stewardship and diagnostic framework may improve survival.
|
Medicine (2025) - Network Meta-Analysis
Key Findings
- Compared with nucleos(t)ide analogues, MSC plus plasma exchange, DPMAS plus plasma exchange, G-CSF, MSC, and plasma exchange increased the odds of 90-day survival (OR 4.58, 2.95, 2.32, 2.36, and 1.91, respectively).
- MSC plus plasma exchange had the highest likelihood of being optimal (0.92) and higher 90-day survival odds than plasma exchange (OR 2.40, 95% CI 1.05-5.51) or glucocorticoids (OR 2.86, 95% CI 1.01-8.09); G-CSF ranked highest among single-drug regimens (0.58).
📋 Practice Implication: The network estimates can inform comparative adjunct selection in HBV-related acute-on-chronic liver failure, but combination rankings remain hypothesis-generating and require confirmation in direct trials.
|
|
💡
Summary
Recent evidence highlights a time-sensitive role for pre-emptive CRRT in acute liver failure with cerebral edema and for empirical antifungal therapy when invasive fungal infection is suspected in acute-on-chronic liver failure. Artificial liver support improves biochemical detoxification, while comparative and systematic-review evidence shows uncertain mortality benefit for liver support systems overall and suggests that combination strategies may improve 90-day survival in HBV-related acute-on-chronic liver failure.
|
|